![]() ![]() | ||||||||||
|
|
![]() |
![]() |
![]() |
![]() |
![]() |
||||
|
![]() |
![]() |
Weekly |
![]() |
![]() |
July 13, 2001 / 50(27);582-5 |
![]() |
![]() |
![]() |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Notice to Readers: Delayed Influenza Vaccine Availability for 2001--02 Season and Supplemental Recommendations of the Advisory Committee on Immunization PracticesManufacturer projections of vaccine distribution for the 2001--02 influenza season suggest that 49.8 million doses will be available for delivery by the end of October 2001;* this is approximately 26 million fewer doses of influenza vaccine than were available by the end of October 1999 (75.8 million doses) (Figure 1). Manufacturers also project distribution of 27.3 million doses in November and December, bringing the cumulative projected total to 77.1 million doses, which is greater than in 2000 (70.4) and comparable with 1999 (76.8). Predictions of monthly vaccine distribution vary by manufacturer, and providers will probably receive vaccine on different schedules. Because of the 2001--02 influenza season vaccine delay and the large number of doses projected for distribution in November and December, the Advisory Committee on Immunization Practices (ACIP) has developed supplemental recommendations. The goals of these recommendations are 1) to prioritize and phase in using vaccine for the 2001--02 influenza season to ensure that persons at greatest risk for severe influenza and its complications and their health-care providers receive vaccine early in the influenza season, and 2) to increase overall protection of those at greatest risk for severe influenza and its complications as targeted in the Healthy People 2010 objectives (1). Persons at high risk include those aged >65 years; nursing home and other chronic-care facility residents; adults and children with chronic disorders of the pulmonary and cardiovascular systems, including asthma; adults and children who required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes), renal dysfunction, hemoglobinopathies, or immunosuppression, including that caused by medications or human immunodeficiency virus; children and teenagers (aged 6 months--18 years) who receive long-term aspirin therapy; and women who will be in the second or third trimester of pregnancy during the influenza season (2). Achieving influenza vaccination goals will require the combined actions of vaccine providers; the public; manufacturers, distributors, and vendors; and health departments and other organizations providing vaccine.
ACIP Supplemental Recommendations for 2001--02 Influenza SeasonVaccine Providers
The Public
Manufacturers, Distributors, and Vendors
Health Departments and Other Organizations
As preparation for the 2001--02 influenza season proceeds, updates on vaccine supply, and other information about influenza vaccination that may be helpful to providers and health departments, will be available at http://www.cdc.gov/nip/flu. References
* Manufacturers predict vaccine production based on anticipated demand, production capacity, historic and current experience with yield of vaccine, and duration of production. Accuracy of predictions may be affected by production problems such as strain yields, lot failure, or good manufacturing practices (GMP) issues. One manufacturer that did not produce vaccine in 2000 because of GMP problems has withdrawn from the market. † Within a high-risk household, either when the person at risk or the household contact is a young previously unvaccinated child aged <9 years who requires 2-doses for protection, earlier vaccination of contacts may be reasonable; however, this should be a lower priority than vaccination of high-risk persons. Figure 1 ![]() Return to top. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 7/13/2001 |
![]() |
|||||||
This page last reviewed 7/13/2001
|